56.51
-2.03 (-3.47%)
| Previous Close | 58.54 |
| Open | 58.39 |
| Volume | 331,650 |
| Avg. Volume (3M) | 680,518 |
| Market Cap | 4,345,048,576 |
| Price / Sales | 2.98 |
| Price / Book | 6.19 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -1.73% |
| Operating Margin (TTM) | -3.73% |
| Diluted EPS (TTM) | -0.430 |
| Quarterly Revenue Growth (YOY) | 9.20% |
| Quarterly Earnings Growth (YOY) | -81.70% |
| Total Debt/Equity (MRQ) | 153.63% |
| Current Ratio (MRQ) | 2.01 |
| Operating Cash Flow (TTM) | 257.42 M |
| Levered Free Cash Flow (TTM) | 109.53 M |
| Return on Assets (TTM) | 1.65% |
| Return on Equity (TTM) | 0.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | RadNet, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.30 |
|
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 12.75% |
| % Held by Institutions | 91.67% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 81.00 (Truist Securities, 43.34%) | Buy |
| Median | 79.00 (39.80%) | |
| Low | 75.00 (Raymond James, 32.72%) | Buy |
| Average | 78.33 (38.61%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 70.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 03 Sep 2025 | 79.00 (39.80%) | Buy | 70.95 |
| Truist Securities | 03 Sep 2025 | 81.00 (43.34%) | Buy | 70.95 |
| Raymond James | 13 Aug 2025 | 75.00 (32.72%) | Buy | 68.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAMES NORMAN R | - | 71.32 | -10,000 | -713,200 |
| KATZ DAVID JEFFREY | - | 73.73 | -4,593 | -338,642 |
| WESDORP CORNELIS | - | 73.41 | -1,000 | -73,405 |
| Aggregate Net Quantity | -15,593 | |||
| Aggregate Net Value ($) | -1,125,247 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 72.97 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KATZ DAVID JEFFREY | Officer | 11 Sep 2025 | Disposed (-) | 4,593 | 73.73 | 338,642 |
| WESDORP CORNELIS | Officer | 11 Sep 2025 | Sell (-) | 500 | 73.73 | 36,865 |
| HAMES NORMAN R | Officer | 10 Sep 2025 | Sell (-) | 10,000 | 71.32 | 713,200 |
| WESDORP CORNELIS | Officer | 09 Sep 2025 | Sell (-) | 500 | 73.08 | 36,540 |
| Date | Type | Details |
|---|---|---|
| 08 Sep 2025 | Announcement | RadNet, Inc. to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025 |
| 07 Aug 2025 | Announcement | DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™ |
| 25 Jul 2025 | Announcement | RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call |
| 17 Jul 2025 | Announcement | RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD |
| 09 Jul 2025 | Announcement | Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet’s AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |